PPARG and metabolic dysfunction-associated steatohepatitis: A novel, deuterium-stabilized R-pioglitazone, PXL065, that lacks PPAR-gamma activity but exerts its non-genomic target activities (mitochondrial pyruvate carrier and acyl-CoA synthetase 4 inhibition) has been tested in a phase 2 trial in non-cirrhotic patients with NASH (NCT04321343).